5 例犬脾脏边缘带淋巴瘤（2001-2008 年）。
Splenic marginal zone lymphoma in 5 dogs (2001-2008).
机构信息
Department of Veterinary Clinical Sciences, School of Veterinary Medicine, University of Milan, Milan, Italy.
出版信息
J Vet Intern Med. 2011 Jan-Feb;25(1):90-3. doi: 10.1111/j.1939-1676.2010.0639.x. Epub 2010 Nov 23.
BACKGROUND
Splenic marginal zone lymphomas (MZL) in dogs arise from the marginal zone of B-cell follicles and can progress slowly.
OBJECTIVES
To describe clinical features, treatment, and outcome of dogs with splenic MZL.
ANIMALS
Five dogs with naturally occurring MZL.
METHODS
Clinical, laboratory, and follow-up data were retrospectively reviewed. Diagnosis was based on clinical, histopathological, and immunophenotypic features.
RESULTS
All dogs had stage IV disease; among them, 2 were symptomatic (substage "b") because of splenic rupture. Four dogs underwent splenectomy and adjuvant doxorubicin, and 1 dog underwent surgery only. Three out of the 4 dogs treated with surgery and chemotherapy died of causes unrelated to lymphoma, after 760, 939, and 1,825 days, whereas the remaining dog was alive and in complete remission after 445 days. The dog not receiving any adjuvant treatment had recurrence of the tumor after 180 days.
CONCLUSIONS AND CLINICAL IMPORTANCE
Splenic MZL appears indolent and can benefit from splenectomy, with or without systemic chemotherapy.
背景
犬脾脏边缘区淋巴瘤（MZL）起源于 B 细胞滤泡的边缘区，且可能发展缓慢。
目的
描述患有脾脏 MZL 的犬的临床特征、治疗方法和预后。
动物
5 只患有自发性 MZL 的犬。
方法
回顾性分析临床、实验室和随访数据。诊断基于临床、组织病理学和免疫表型特征。
结果
所有犬均患有 IV 期疾病；其中，2 只因脾脏破裂而出现症状（亚期“b”）。4 只犬接受了脾切除术和辅助阿霉素治疗，1 只犬仅接受了手术。接受手术和化疗治疗的 4 只犬中，有 3 只分别在 760、939 和 1825 天后因与淋巴瘤无关的原因死亡，而另 1 只犬在 445 天后仍存活且完全缓解。未接受任何辅助治疗的犬在 180 天后肿瘤复发。
结论和临床意义
脾脏 MZL 似乎呈惰性，可从脾切除术（伴或不伴全身化疗）中获益。
Zotero 插件